Impact of coronary sirolimus-eluting stents on long-term outcome in diabetic patients.
- Author:
Yue-hua FANG
1
;
Wei-feng SHEN
;
Rui-yan ZHANG
;
Jian-sheng ZHANG
Author Information
- Publication Type:Journal Article
- MeSH: Coronary Disease; therapy; Diabetic Angiopathies; therapy; Female; Humans; Male; Retrospective Studies; Sirolimus; administration & dosage; Stents
- From: Chinese Journal of Cardiology 2005;33(5):438-440
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo analyse the impact of sirolimus-eluting stents (SES) on long-term outcomes in patients with coronary artery disease (CAD) and diabetes.
METHODSAmong 1004 patients with CAD undergone percutaneous coronary intervention (PCI), 84 diabetic and 250 non-diabetic patients received SES, 168 diabetic and 502 non-diabetic patients had bare metal stent (BMS) implantation. Baseline clinical characteristics, interventional procedures (coronary angiography and PCI), occurrence of major adverse cardiac events (MACE), and MACE-free survival rates at one year during follow-up were compared.
RESULTSDuring follow-up (average 16.2 months), patients (with and without diabetes mellitus) who received SES had similar occurrence of MACE (4.8% vs. 3.6%, P = 0.744) and MACE-free survival rates at one year (95.0% vs. 96.7%, P = 0.602). However those received BMS had a higher occurrence of MACE in diabetes mellitus than that in non-diabetic patients (31.0% vs. 21.7%, P = 0.015). MACE-free survival rate at one year was lower in diabetic patients with BMS than that in non-diabetic patients with BMS (74.2% vs. 86.8%, P = 0.001).
CONCLUSIONImplantation of sirolimus-eluting stents may reduce the major adverse cardiac events and the frequency of repeat intervention in patients with diabetes mellitus.
